Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain:: 1994-1996 and 1997-2005

被引:15
作者
Aller, A. I.
Claro, R.
Castro, C.
Serrano, C.
Colom, M. F.
Martin-Mazuelos, E.
机构
[1] Hosp Valme, Serv Microbiol, Seville, Spain
[2] Hosp Miguel Hernandez, Fac Med, Dept Microbiol, Alicante, Spain
关键词
cryptococcal susceptibilities; Spain;
D O I
10.1159/000102585
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antifungal drug susceptibility of 70 Cryptococcus neoformans isolates obtained in Spain from 1994 to 1996 (23 isolates) and from 1997 to 2005 (47 isolates) was investigated. The MICs of fluconazole, itraconazole and voriconazole were determined by the modified Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) broth microdilution method. The MIC50 and MIC90 for itraconazole and voriconazole did not change significantly from 1994 to 2005. The MIC50 of fluconazole remained stable and the MIC90 decreased by 2 log(2) dilution in the isolates collected from 1997 to 2005. We conclude that the in vitro resistance to fluconazole decreased over an 11-year period. In addition, a tendency for the development of possible cross-resistance between the three triazoles was observed. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:300 / 305
页数:6
相关论文
共 28 条
[21]  
Pfaller MA, 1999, ANTIMICROB AGENTS CH, V43, P169, DOI 10.1093/oxfordjournals.jac.a020873
[22]   A CONTROLLED TRIAL OF FLUCONAZOLE OR AMPHOTERICIN-B TO PREVENT RELAPSE OF CRYPTOCOCCAL MENINGITIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
POWDERLY, WG ;
SAAG, MS ;
CLOUD, GA ;
ROBINSON, P ;
MEYER, RD ;
JACOBSON, JM ;
GRAYBILL, JR ;
SUGAR, AM ;
MCAULIFFE, VJ ;
FOLLANSBEE, SE ;
TUAZON, CU ;
STERN, JJ ;
FEINBERG, J ;
HAFNER, R ;
DISMUKES, WE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (12) :793-798
[23]   CRYPTOCOCCAL MENINGITIS AND AIDS [J].
POWDERLY, WG .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (05) :837-842
[24]  
POWDERLY WG, 1992, INFECT DIS CLIN PRAC, V1, P314
[25]   Practice guidelines for the management of cryptococcal disease [J].
Saag, MS ;
Graybill, RJ ;
Larsen, RA ;
Pappas, PG ;
Perfect, JR ;
Powderly, WG ;
Sobel, JD ;
Dismukes, WE .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :710-718
[26]   Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates:: April 2000 to March 2002 [J].
Sar, B ;
Monchy, D ;
Vann, M ;
Keo, C ;
Sarthou, JL ;
Buisson, Y .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :563-565
[27]  
SHEEHAN DJ, 2005, 15 EUR C CLIN MICR I, P1740
[28]   In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592) [J].
Yildiran, ST ;
Fothergill, AW ;
Sutton, DA ;
Rinaldi, MG .
MYCOSES, 2002, 45 (9-10) :378-383